Lantus

DM in adults, adolescents, & childn ≥2 yr.

SC Inj sites must be rotated w/in given inj area from 1 inj to the next. Individualised dose. Administer once daily, at any time of the day, at the same time every day.

Hypersensitivity.

Not to be administered IV. Not to be used w/ any other reusable pen except for ClikStar, OptiPen, TactiPen, Autopen 24 & AllStar. Potential risk of delayed insulin absorption & worsened glycemic control following insulin inj. Hypo-/hyperglycemia. Patients w/ significant narrowing of coronary arteries or of blood vessels supplying brain, or those w/ certain eye disease related to diabetes (proliferative retinopathy), particularly when not treated w/ photocoagulation (risk of transient blindness); in whom blood sugar control is markedly improved, hypoglycaemia develops gradually, certain type of nervous disease (autonomic neuropathy) is present, w/ long history of diabetes, suffering from psychiatric illness or receiving concurrent treatment w/ certain other medicines. Instruct patient in skills for diabetes self-management eg, blood sugar monitoring, proper inj technique, measures for recognizing & managing hypo-/hyperglycaemia; handling special situations eg, skipped, inadequate or increased insulin doses, inadequate food intake or missed meals. Perform continuous rotation of inj site to reduce risk of developing lipodystrophy & localized cutaneous amyloidosis. Consider blood glucose monitoring after change in inj site & dose adjustment of antidiabetic medications. Close monitoring on factors increasing hypoglycaemia risk eg, change in inj area (eg, from thigh to upper arm); improved insulin sensitivity by eg, removal of stress factors; unaccustomed or increased physical activity; concomitant illness (eg, vomiting, diarrhoea); inadequate food intake eg, missed or delayed meals, smaller than usual meals or w/ less carbohydrate content than normal (sweet & starchy food), changes in diet; alcohol consumption; certain uncompensated endocrine disorders eg, reduced thyroid function or anterior pituitary or adrenocortical insufficiency; concurrent use of other medicines. Carry out tests for blood sugar or ketones in urine as soon as symptoms of hyperglycemia occur & in patients w/ concomitant illness. May affect ability to operate vehicle or perform hazardous tasks. Severe hepatic & moderate to severe renal impairment. Maintain good metabolic control during pregnancy in women w/ preexisting or gestational diabetes. May decrease insulin requirements in the 1st 3 mth & increased during 2nd & 3rd trimester of pregnancy. Adjust dosage & diet in breast-feeding women. Childn <2 yr. Elderly.

Hypoglycemia; temporary visual impairment; lipoatrophy or lipohypertrophy, reddening, unusually intense pain, itching, hives, swelling or inflammation, & localized cutaneous amyloidosis at inj site.

Increased blood-sugar-lowering effect & susceptibility to hypoglycaemia w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, or sulfonamide antibiotics. Decreased blood-sugar-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens (eg, OCs), phenothiazine derivatives, somatropin, sympathomimetic agents (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. Either potentiated or weakened blood-sugar-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypo-/hyperglycaemia w/ pentamidine. Weakened or suppressed warning symptoms of hypoglycaemic reaction w/ β-blockers, other sympatholytics eg, clonidine, guanethidine, reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

D